ArticleLeukemia & lymphoma2020
Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).
Article in Leukemia & lymphoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment.Acta dermato-venereologica · 2026Article
- Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma.Allergy · 2026Article
- Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome.Frontiers in oncology · 2026Review
- Skin microbiota differs between Black and White patients with cutaneous T-cell lymphoma.Journal of the American Academy of Dermatology · 2025Article
- LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell Lymphoma.JCI insight · 2025Article
- Article
- Role of Antigenic Stimulation in Cutaneous T-Cell Lymphomas.The Journal of investigative dermatology · 2024Review
- Vitamin D in Cutaneous T-Cell Lymphoma.Cells · 2024Review
- Reply to Wu et al's US SEER analysis of sepsis in Black patients with CTCL.Journal of the American Academy of Dermatology · 2024Article
- Evaluation of Blood Culture Results in Patients with Malignancy in Erzurum Province, Turkey.Acta medica Lituanic · 2024Article
- DMF in CTCL: where do we go from here?Blood · 2023Article
- Retrospective analysis of sepsis in cutaneous T-cell lymphoma reveals significantly greater risk in Black patients.Journal of the American Academy of Dermatology · 2023Article
- Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis.Cureus · 2022Article
- [Current therapeutic options in Mycosis fungoides and Sézary syndrome].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with CTCL are at increased risk for bacteremia which is a leading cause of morbidity and mortality. We assessed risk factors for and the impact of bacteremia on survival in a retrospective cohort of 188 CTCL patients at a single US academic institution treated between 1990 and 2018. With a median follow up of 6.2 years, 20% of patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.